Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 11;15:2909–2915. doi: 10.2147/NDT.S222258

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Lin et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Serum cytokine/chemokine changes in anti-LGI1 encephalitis patients.

Notes: Serum CXCL13 (E) levels were higher in anti-LGI1 encephalitis patients than in controls. IL-6 (A), IL-10 (B), IL-17 (C), CXCL12 (D), BAFF (F) and HMGB1 (G) levels were not different between the anti-LGI1 encephalitis group and the control group. *P-value <0.05; ns: p-value >0.05.

Abbreviations: LGI1, anti-leucine-rich glioma inactivated-1; IL, interleukin; CXCL12, stromal cell-derived factor-1; CXCL13, C-X-C motif chemokine 13; BAFF, B cell activation factor; HMGB1, high-mobility group box protein 1.